• Neurocrine Biosciences announced a new analysis establishing a benchmark for clinically meaningful improvement in patient-reported overall health with Ingrezza for tardive dyskinesia.
• The benchmark supports previously reported KINECT-PRO findings showing meaningful improvements in overall health, daily functioning and involuntary movements.
• Findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, Oct. 26-29 in San Diego.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260830PR_NEWS_USPR_____LA79273) on October 26, 2026, and is solely responsible for the information contained therein.